Driving Acceleration in Oncology Trials Through Contemporary Regulatory Strategies

  • Modern FDA Acceleration Pathways: Breakthrough, Fast Track, Accelerated Approval, Priority Review, RTOR, Orbis, CNPV
  • Trial Design Innovations That Regulators Support: adaptive designs, master protocols, biomarker‑driven enrichment
  • Optimizing Early Regulatory Engagement to Enable Acceleration: strategic FDA/EMA interactions, alignment on endpoints and biomarkers

The Intersection of Artificial Intelligence (AI), Sustainability, and the Future of Workforce Transformation

  • The macro outlook that matters to firms: where growth, inflation, interest rates and regulation are heading—and the knock-on impact on client demand and risk.
  • Why advisory is slowing (and what replaces it): shifting client buying behaviour, procurement pressure, and how to reposition offers to protect margin.
  • Pressure points and opportunity zones: where fees will compress (commodity work) versus where demand will rise (cashflow, restructuring, tax/ risk, AI/ ESG assurance, sector specialisation).

The Hidden Costs you can Eliminate with Automation

  • Post‑MTD reality check: what actually changed after implementation, what worked, what broke, and the new compliance “normal.”
  • Where firms still bleed money: persistent cost drains, rework, chasing clients, manual entry, onboarding delays, partner bottlenecks.
  • Next-wave automation wins: the tools and workflow changes that build on MTD to cut friction, speed delivery, and protect margin.